Filing Details

Accession Number:
0001209191-23-049292
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-09-13 16:39:13
Reporting Period:
2023-09-11
Accepted Time:
2023-09-13 16:39:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1759425 Mirum Pharmaceuticals Inc. MIRM () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1365617 J Patrick Heron C/O Frazier Life Sciences
70 Willow Road, Suite 200
Menlo Park CA 94025
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-09-11 4,687 $30.30 152,678 No 4 P Indirect By Frazier Life Sciences X, L.P.
Common Stock Acquisiton 2023-09-12 3,750 $30.60 156,428 No 4 P Indirect By Frazier Life Sciences X, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Frazier Life Sciences X, L.P.
No 4 P Indirect By Frazier Life Sciences X, L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,566,912 Indirect By Frazier Life Sciences IX, L.P.
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.0968 to $30.4835, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
  2. The shares are held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS X, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences X, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $30.2781 to $30.7970, inclusive.
  4. The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. The Reporting Person and James N. Topper are the managing members of FHMLS IX, L.L.C. and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein.